SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Advanced Gastric CancerAdvanced Colorectal CancerAdvanced Ovarian CancerPeritoneal Metastasis
Interventions
RADIATION

Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)

"Radiation: Stereotactic Body Radiation Therapy (SBRT)~* Stereotactic Body Radiation Therapy (SBRT) will be performed first at a total dose of 20-50 Gy, delivered in 3-5 fractions of 6-10 Gy each. And the target area was specifically selected based on the location and size of the patient's tumor.~Radiation: low-dose radiotherapy (LDRT)~* Whole-abdominal low-dose radiotherapy will be initiated within 10 days of the end of SBRT with a total dose of 7-15 Gy at 0.5-2.0 Gy twice daily. And the target area included all suspicious tumor tissues and potential metastatic foci in the abdominal cavity."

DRUG

Cadonilimab

· Cadonilimab: 6 mg/kg IV, D1, Q2W, until disease progression, death, toxicity intolerance or withdrawal of informed consent

Trial Locations (1)

400016

The First Affiliated Hospital of Chongqing Medical University, Chongqing

Sponsors
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Zhang Tao

OTHER